Jump to navigation
The UA and the Arizona Department of Health Services will train first responders to recognize opioid overdoses and administer naloxone, which counters the effects of overdose.
What if an easily administered, biologically based test could determine whether an individual has schizophrenia? "We've got a huge challenge," Dr. Amelia Gallitano says.
The state-of-the-art facility, located east of the UA Cancer Center – North Campus, will have more than two dozen specialties available by mid-January. With UANews video.
Researchers in the College of Medicine – Tucson have invented a new class of non-opioid drug candidates to treat pain, and the UA has licensed the compounds.
Two patents have been awarded to the UA based on the novel approach of ProNeurogen to treating diseases causing memory loss and cognitive impairment.
What if you could experience full health until the very end of your life? UA researchers, led by Dr. Janko Nikolich-Zugich, think long-lasting immunity might be possible — if the thymus and the T-cells it produces to fight infection can be returned to greater efficiency. With UANews video.
A carbon monoxide- and iron-based therapy, under development by the UA's Dr. Vance G. Nielsen, can inhibit venom's effects for up to an hour in animals. It eventually could be delivered with a device similar to an EpiPen autoinjector — and stocked on ambulances and in first-aid kits.
UA beach volleyball player Mia Mason, who survived a rare brain tumor as a 12-year-old, is now paying it forward with a fund to support pediatric cancer research.
Spun out of the College of Pharmacy as a startup company in 2013 with help from Tech Launch Arizona, SinfoníaRx pioneered modern medication therapy management services.
According to the UA's Todd Vanderah, the chemical compounds — unlike opioids — help slow bone loss while also slowing the proliferation of metastatic breast cancer.